Biogen Inc (BIIB)

Biogen Inc. is a biotechnology company whose common stock is listed on NASDAQ under the symbol BIIB. The company discovers, develops, manufactures, and delivers therapies for patients in the United States, Europe, Germany, Asia, and other international markets. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, amyotrophic lateral sclerosis, plaque psoriasis, Alzheimer’s disease, postpartum depression, and several B-cell related cancers and autoimmune conditions. Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, SPINRAZA, SKYCLARYS, QALSODY, LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and other anti-CD20 therapies, along with select biosimilars. The company also maintains collaboration and licensing relationships with multiple biopharmaceutical partners, including Eisai, UCB, Genentech, Ionis, Samsung Bioepis, and Sage Therapeutics. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen remains focused on neurological and related therapeutic areas.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BIIB
$267.34
6.6% Upside
Fair
$268.26
7.0% Upside
Fair
Good
0.0%
February 17, 2027
106.7x
2.0x
3.6x
37.072 B
43.111 B
17.3%
99.6%
6.2
595.9%
Valuation • Fair Value

Biogen Inc (NASDAQ-BIIB) Fair Value by Valuation Model

Review the available estimates for Biogen Inc (NASDAQ-BIIB), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$267.34

Estimated upside of 6.6% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$307.34

Discounted cash flow valuation reference.

Ben Graham Formula Value

$26.08

Classic Ben Graham valuation formula reference.

EPV Fair Value

$264.53

Earnings power value estimate.

Comps Fair Value

$227.79

Comparable-company valuation reference.

Analyst Price Target

$268.26

Analysts imply upside of 7.0%.

How to read these valuation models

Use the 7 available valuation references for Biogen Inc (NASDAQ-BIIB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biogen Inc (NASDAQ-BIIB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

10.297 B

Current operating scale indicator.

Revenue Forecast

10.567 B

Forward revenue estimate.

EBITDA

3.302 B

Current operating profitability reference.

EBITDA Forecast

2.787 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Biogen Inc (NASDAQ-BIIB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biogen Inc (NASDAQ-BIIB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.58

No elevated caution signal from this screen.

Altman Z-Score

6.2

Relatively strong balance-sheet zone.

FCF / Net Income

595.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biogen Inc (NASDAQ-BIIB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Biogen Inc (NASDAQ-BIIB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 17, 2027

Days to Earnings

91

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Biogen Inc (NASDAQ-BIIB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Biogen Inc (NASDAQ-BIIB) Stock Forecast & Technical Outlook

Review Biogen Inc (NASDAQ-BIIB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Biogen Inc (NASDAQ-BIIB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Biogen Inc (NASDAQ-BIIB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Biogen Inc (NASDAQ-BIIB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Biogen Inc (NASDAQ-BIIB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Biogen Inc (NASDAQ-BIIB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Biogen Inc (NASDAQ-BIIB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Biogen Inc (NASDAQ-BIIB) has a Buy consensus, with 21 buy, 10 hold and 1 sell recommendations in the current data set.

Buy 21
Hold 10
Sell 1
FAQ • Fast Investor Answers

Biogen Inc (NASDAQ-BIIB) Stock FAQ

Data-supported answers about Biogen Inc (NASDAQ-BIIB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$267.34
Estimated upside 6.6%
Valuation Rating
Undervalued
Estimated upside of 6.6%
Analyst Target
$268.26
Implied upside 7.0%
Financial Health
Good
Current financial-health read

The current fair value estimate for Biogen Inc (NASDAQ-BIIB) is $267.34. This implies an estimated upside of 6.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.6% versus the current market price.

The available analyst price target for Biogen Inc (NASDAQ-BIIB) is $268.26. The analyst target implies estimated upside of 7.0%.

The current financial health read for Biogen Inc (NASDAQ-BIIB) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Biogen Inc (NASDAQ-BIIB) is February 17, 2027.

The latest available data indicates no current dividend yield for Biogen Inc (NASDAQ-BIIB).

The current P/E ratio listed for Biogen Inc (NASDAQ-BIIB) is 106.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Biogen Inc is 37.072 B.

The current enterprise value listed for Biogen Inc is 43.111 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biogen Inc is NASDAQ-BIIB, and the stock is listed on NASDAQ.

Biogen Inc (NASDAQ-BIIB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Biogen Inc is 17.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Biogen Inc is 99.6%. Free float helps investors understand how much of the share base is available for public trading.